Hemostemix Inc. (CVE:HEM – Get Free Report) shot up 27.8% during trading on Saturday . The stock traded as high as C$0.12 and last traded at C$0.12. 335,071 shares traded hands during trading, a decline of 31% from the average session volume of 486,759 shares. The stock had previously closed at C$0.09.
Hemostemix Price Performance
The company has a quick ratio of 0.48, a current ratio of 0.04 and a debt-to-equity ratio of -55.07. The firm’s 50 day simple moving average is C$0.10 and its 200 day simple moving average is C$0.14. The company has a market capitalization of C$16.76 million, a PE ratio of -3.35 and a beta of 0.20.
Insiders Place Their Bets
In related news, Director Peter Alan Lacey bought 200,000 shares of the stock in a transaction dated Thursday, March 6th. The stock was purchased at an average cost of C$0.15 per share, with a total value of C$30,000.00. 10.43% of the stock is owned by insiders.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Recommended Stories
- Five stocks we like better than Hemostemix
- Market Cap Calculator: How to Calculate Market Cap
- Apple’s Quiet HomePad Delay Could Be Its Loudest Move Yet
- Insider Trades May Not Tell You What You Think
- e.l.f. Gets Back on the Shelf! It’s Not Too Late to Buy In!
- What is the Dogs of the Dow Strategy? Overview and Examples
- Near 52-Week Lows, These 3 Mid-Cap Stocks Are Worth a Look
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
